JBJacquelyn Baskin‐Miller

Jacquelyn Baskin‐Miller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jacquelyn Baskin‐Miller has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Virtual Transition Assessments in Sickle Cell Disease Are Feasible and Available Transition Instruments May Highlight Different Components of the Transition Experience

    by Alexandra Boye‐Doe, Samuel Wilson, Lindsey Akpuogu, Jane Little, Jacquelyn Baskin‐Miller

    There is increased morbidity and mortality during the transition to adult care in sickle cell disease. Standardized implementation of validated transition tools may improve readiness for transition (RFT). We tested the impact of telehealth on this process by comparing in‐person or via telehealth administration of the provider‐administered tool, TRxANSITION Index (TI), to the patient‐reported tool, transition intervention program‐RFT (TIP‐RFT) in patients 15–21 years old. Scores between testing given in person or via telehealth did not differ (p > 0.9, N = 20). TIP‐RFT scores were up to 14% higher than TI. Our results indicate that telehealth transition tools are feasible and are acceptable to providers and participants. Our data also suggest that the more objective TI may be most sensitive in detecting transition needs; this awaits validation.


  • Transfusional hemosiderosis in childhood cancer patients and survivors

    by Jacquelyn Baskin‐Miller, Susan Carson, Julie Jaffray, Craig Fletcher, Jessie Singer, David R. Freyer, John Wood, Thomas D. Coates, Christopher C. Denton

    Background: Children treated for cancer are at risk for adverse effects of iron due to transfusions administered during prolonged marrow suppression, which may increase exposure to toxic forms of iron, extrahepatic iron accumulation, and long‐term organ damage.Objective: This study aimed to characterize the severity and organ distribution of clinically significant, multisystem iron overload (IO) in an at‐risk cohort of pediatric cancer patients.Methods: This was a retrospective, cross‐sectional study of childhood cancer patients who underwent a magnetic resonance imaging (MRI) due to clinical concern for IO. Data regarding cancer type and treatment, transfusion history, MRI and laboratory results, and treatment for IO were collected. Severity of IO was analyzed by non‐parametric tests with respect to clinical characteristics.Results: Of the 103 patients, 98% of whom had a Cancer Intensity Treatment Rating (ITR‐3) of 3 or higher, 53% (54/102) had moderate or greater hepatic siderosis, 80% (77/96) had pancreatic siderosis, 4% (3/80) had cardiac siderosis, and 45% (13/29) had pituitary siderosis and/or volume loss. Pancreatic iron was associated with both cardiac (p = .0043) and pituitary iron (p = .0101). In the 73 off‐therapy patients, ferritin levels were lower (p = .0008) with higher correlation with liver iron concentration (LIC) (p = .0016) than on‐therapy patients. Fifty‐eight subjects were treated for IO.Conclusion: In this heavily treated cohort of pediatric cancer patients, more than 80% had extrahepatic iron loading, which occurs with significant exposure to toxic forms of iron related to decreased marrow activity in setting of transfusions. Further studies should examine the effects of exposure to reactive iron on long‐term outcomes and potential strategies for management.


  • Open Access

    Transfusional Hemosiderosis in Childhood Cancer Patients and Survivors

    by Jacquelyn Baskin, Susan Carson, Julie Jaffray, David Freyer, John Wood, Thomas Coates, Christopher Denton

    Background: Children treated for cancer are at risk of developing iron toxicity due to receiving red cell transfusions and myelosuppressive chemotherapy. Transfusions administered during prolonged episodes of marrow suppression may increase exposure to toxic, reactive forms of iron and thereby increase risk of extrahepatic iron accumulation and long-term organ damage. Objective: This study aimed to evaluate the severity and organ distribution of clinically significant iron overload through measurement of hepatic, cardiac, pancreatic, and pituitary iron deposition in an at-risk cohort of children and young adults treated for cancer. Methods: This retrospective study evaluated patients treated for any type of cancer who underwent an MRI due to clinical concern for evaluation of iron overload (n=103, 73 post-treatment). Data regarding cancer type and treatment, MRI and laboratory results, and treatment for iron overload were analyzed. Results: Over half (53%) of this sample had moderate or greater hepatic siderosis, 80% had pancreatic siderosis, and nearly half (45%) had pituitary siderosis and/or volume loss. Pancreatic iron was associated with both cardiac (p=0.0043) and pituitary iron (p=0.0101). Patients treated for acute myeloid leukemia or high-risk acute lymphoblastic leukemia had higher liver iron concentration (LIC) compared to other cancer types (median LIC 8.5 vs. 2.9 mg/g DLW, p=0.0011). Conclusion: Pediatric cancer patients are at risk for transfusional iron overload, with significant exposure to toxic forms of iron indicated by extrahepatic iron deposition (pancreas, heart and pituitary). Further studies should examine the effect of exposure to reactive iron on long-term outcomes and develop management recommendations.

  • Open Access

    Utilization, trust and satisfaction with health care in adult sickle cell disease patients

    by Jacquelyn Baskin, Anne Nord, Dawn Canada, Kelly Russell, Payal Shah, Thomas Coates, Arch Mainous

    Introduction: Transition from pediatric to adult care for emerging adults with sickle cell disease (SCD) has been challenging due to limited availability of experienced adult providers and patient difficulty navigating the adult health care system. The purpose of this study was to determine among adults with SCD, healthcare utilization and their trust and satisfaction with their health care provider. Methods: We surveyed adult patients greater than 21 years old with SCD previously transitioned from Children’s Hospital Los Angeles. Assessments of provider trust and satisfaction were conducted along with health care utilization and the transition experience. Results: Of 31 participants, 61% and 68% identified having an adult primary care provider (PCP) and adult hematologist respectively. Increased satisfaction with care was associated with increased trust in the adult hematologist (r=0.72 p<0.001) and PCP (r=0.76 p=0.001) and improved communication (p< 0.001). Trust in their hematologist was greater than PCP (76.5 vs 64.2, p = 0.058). For SCD complications, 65% of participants visited the ED, 80% of whom had negative experiences including sub-optimal pain management. Regarding transition experience, 55% felt unprepared for adult care. Discussion: More than 30% of adult SCD patients transferred out of pediatric care are not receiving regular hematology care for their SCD, resulting in fragmented medical care. Increased trust in their adult hematologist and clear communication are associated with higher levels of satisfaction with care. These findings will be utilized to develop a transition program to improve patient preparation and build on partnerships with adult providers to improve long-term outcomes.